Clinical Trial: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda(R) in Multiple Resected Solid Tumors

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07160335) titled 'A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda(R) in Multiple Resected Solid Tumors' on Aug. 22.

Brief Summary: This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda(R) in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).

Study Start Date: Sept. 16

Study Type: INTERVENTIONAL

Condition: Non-small Cell Lung Cancer Melanoma Renal Cell Carcinoma

Intervention: DRUG...